<p class="jove_content">In a prospective cohort of 200 patients with gastrointestinal stromal tumor (GIST) receiving first-line imatinib, a baseline five-metabolite plasma panel independently predicted progression-free survival. Internal validation showed improved discrimination and calibration over a clinical benchmark, supporting further external evaluation of the panel as a prognostic risk-stratification tool.</p>

a-5-metabolite-plasma-panel-predicts-progression-free-survival-adds

A 5-Metabolite Plasma Panel Predicts Progression-Free Survival and Adds Prognostic Value in Imatinib-Treated Gastrointestinal Stromal Tumors

Among patients with gastrointestinal stromal tumor receiving first-line imatinib, outcomes vary substantially, and traditional stratification based on ...

Institution - Chongzhou People's Hospital

Articles Published in JoVE